Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-110721-4df69d8e",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "mini-max",
  "action": "synthesize",
  "content": "\n\n{\"ranked_hypotheses\":[{\"title\":\"H1: ALX/FPR2 Exhibits Ligand-Dependent Bias in β-Arrestin Recruitment\",\"description\":\"ALX/FPR2 demonstrates ligand-selective desensitization patterns where SPM agonists (e.g., LXA4, RvD1) induce minimal β-arrestin2 recruitment compared to classical chemoattractants (fMLF). This biased agonism results in preferential G-protein coupling with limited receptor internalization. While the biased agonism concept is supported by Chiang et al. (2015), the leap from differential β-arrestin recruitment to absence of desensitization is not fully justified as alternative GRK-independent mechanisms may exist. High druggability supported by available structural data and measurable endpoints.\",\"target_gene\":\"ALX/FPR2 (FPR2), β-arrestin2 (ARRB2), GRK2/3\",\"composite_score\":0.72,\"evidence_for\":[{\"claim\":\"RvD1 induces G-protein signaling without β-arrestin recruitment at ALX/FPR2; fMLF triggers robust β-arrestin coupling\",\"pmid\":\"26236997\"},{\"claim\":\"ALX/FPR2 structure available; ligand-binding pockets characterized\",\"pmid\":\"25848862\"}],\"evidence_against\":[{\"claim\":\"Sustained LXA4 signaling induces receptor downregulation in neutrophils\",\"pmid\":\"25947339\"},{\"claim\":\"ALX/FPR2 undergoes significant internalization following RvD1 treatment\",\"pmid\":\"26898797\"},{\"claim\":\"Low β-arrestin recruitment does not equate to absence of desensitization (GRK-independent PKA-mediated desensitization, RGS protein upregulation possible)\",\"pmid\":\"NA\"}]},{\"title\":\"H5: Differential Desensitization Susceptibility Explains Therapeutic Hierarchy of SPMs\",\"description\":\"Individual SPMs exhibit rank-order desensitization potencies at ALX/FPR2 (proposed order: fMLF > LXA4 > RvD1 > Maresin-1), explaining variable efficacy with repeated dosing. RvD1 demonstrates superior resistance to desensitization, supporting priority development for chronic priming. The hypothesis enables formulary optimization rather than new drug development. Critical validation needed as rank-order claim is currently asserted without systematic demonstration.\",\"target_gene\":\"ALX/FPR2 (FPR2), multiple SPM ligands (RvD1, LXA4, Maresin-1)\",\"composite_score\":0.65,\"evidence_for\":[{\"claim\":\"Structure-activity relationships at ALX/FPR2 demonstrate SPMs bind in distinct receptor conformations\",\"pmid\":\"25848862\"},{\"claim\":\"Unique structural features of resolvins may prevent GRK recognition\",\"pmid\":\"26236997\"}],\"evidence_against\":[{\"claim\":\"Rank-order claim is asserted without citation or systematic measurement\",\"pmid\":\"NA\"},{\"claim\":\"Differential efficacy may reflect pharmacokinetics (RvD1 shorter half-life) not receptor desensitization\",\"pmid\":\"NA\"},{\"claim\":\"Clinical failures attributed to bioavailability issues, not desensitization patterns\",\"pmid\":\"NA\"}]},{\"title\":\"H6: β-Arrestin-Dependent ALX/FPR2 Signaling Generates Protective Desensitization Feedback\",\"description\":\"Rather than terminating signaling, β-arrestin recruitment to ALX/FPR2 initiates pro-resolving programs including p38 MAPK activation and COX-2 upregulation for SPM synthesis. This creates autocrine feedback where receptor internalization scaffolds β-arrestin signalosomes driving cellular reprogramming toward resolution. Presents conflicting strategy with H1 (minimize vs. maximize β-arrestin) requiring resolution through context-dependent development.\",\"target_gene\":\"ALX/FPR2 (FPR2), β-arrestin1/2 (ARRB1/2), p38 MAPK (MAPK14), COX-2 (PTGS2)\",\"composite_score\":0.60,\"evidence_for\":[{\"claim\":\"Arrestin-dependent signaling recognized as functional receptor output rather than termination mechanism\",\"pmid\":\"25926524\"},{\"claim\":\"β-arrestin signalosomes can drive cellular reprogramming in other GPCR systems\",\"pmid\":\"24900359\"}],\"evidence_against\":[{\"claim\":\"Conflicting with H1: H1 requires β-arrestin avoidance for sustained signaling; H6 requires β-arrestin recruitment for protective feedback\",\"pmid\":\"NA\"},{\"claim\":\"β-arrestin biased GPCR agonists have mixed clinical track records (TRV027 failed Phase II)\",\"pmid\":\"NA\"},{\"claim\":\"β-arrestin pathways are pleiotropic; unintended pro-inflammatory signaling possible\",\"pmid\":\"NA\"}]},{\"title\":\"H3: Heterologous Desensitization of ALX/FPR2 by Pro-inflammatory Mediators\",\"description\":\"Pre-exposure to inflammatory mediators (TNF-α, IL-1β) induces heterologous desensitization of ALX/FPR2 through PKC-mediated phosphorylation uncoupling receptor from G-protein signaling. Creates therapeutic window problem where chronic inflammation may render SPM priming ineffective. Druggability is LOW-MODERATE as systemic PKC inhibitors have failed clinically; hypothesis more suitable for biomarker/patient stratification development than direct drug targeting.\",\"target_gene\":\"ALX/FPR2 (FPR2), PKC isoforms, GRK2\",\"composite_score\":0.56,\"evidence_for\":[{\"claim\":\"PKC-mediated heterologous desensitization documented for FPR family members\",\"pmid\":\"12154119\"},{\"claim\":\"FPR2 possesses PKC consensus sites (Ser321, 322) identified through sequence analysis\",\"pmid\":\"NA\"}],\"evidence_against\":[{\"claim\":\"TNF-α actually increases ALX/FPR2 expression in certain contexts, contradicting desensitization\",\"pmid\":\"28516932\"},{\"claim\":\"Systemic PKC inhibitors (sotrastaurin, ruboxistaurin) have failed in clinical trials due to toxicity\",\"pmid\":\"NA\"},{\"claim\":\"PKC isoforms have redundant pathways; selective targeting challenging\",\"pmid\":\"NA\"}]},{\"title\":\"H7: FPR2/FPR1 Heterodimerization Alters Desensitization Kinetics\",\"description\":\"ALX/FPR2 forms functional heterodimers with FPR1, altering desensitization profile with heterodimers showing delayed internalization and enhanced G-protein signaling duration. Provides mechanistic explanation for variable desensitization responses. LOW-MODERATE druggability due to challenging protein-protein interface targeting and weak mechanistic evidence. Pre-competitive for drug development; mechanism establishment required first.\",\"target_gene\":\"ALX/FPR2 (FPR2), FPR1, β-arrestin2 (ARRB2)\",\"composite_score\":0.52,\"evidence_for\":[{\"claim\":\"FPR1/FPR2 heterodimerization documented in literature\",\"pmid\":\"22842606\"},{\"claim\":\"Dimerization alters GPCR pharmacology including desensitization kinetics in other receptor systems\",\"pmid\":\"23152434\"}],\"evidence_against\":[{\"claim\":\"Direct evidence for altered desensitization patterns in FPR dimers missing\",\"pmid\":\"NA\"},{\"claim\":\"Dimer interface not well-characterized; no specific dimerization domain identified\",\"pmid\":\"NA\"},{\"claim\":\"PPI surfaces notoriously difficult to target with small molecules\",\"pmid\":\"NA\"}]},{\"title\":\"H2: GPR32 Undergoes Rapid Homologous Desensitization via GRK6 Phosphorylation\",\"description\":\"GPR32 undergoes classical homologous desensitization following RvD1 activation with GRK6-mediated phosphorylation at conserved serine/threonine residues leading to β-arrestin2 recruitment, receptor internalization via clathrin-coated pits, and lysosomal degradation. LOW PRIORITY: No direct experimental evidence exists; structural homology argument is weak as many Gi-coupled receptors show dramatically different desensitization kinetics despite sequence similarities.\",\"target_gene\":\"GPR32 (GPR32), GRK6, β-arrestin2 (ARRB2)\",\"composite_score\":0.42,\"evidence_for\":[{\"claim\":\"GPR32 shares structural homology with other Gi-coupled receptors known to undergo GRK-mediated desensitization\",\"pmid\":\"NA\"},{\"claim\":\"Conservation of putative GRK phosphorylation sites in GPR32 C-terminal domain (identified through sequence analysis)\",\"pmid\":\"NA\"}],\"evidence_against\":[{\"claim\":\"No established literature on GPR32 desensitization exists - zero papers directly measuring phosphorylation or internalization\",\"pmid\":\"NA\"},{\"claim\":\"GRK6 specificity unjustified; other GRKs also phosphorylate GPCRs\",\"pmid\":\"NA\"},{\"claim\":\"Lysosomal degradation stated as fact but not demonstrated; many Gi-coupled receptors undergo recycling\",\"pmid\":\"NA\"}]},{\"title\":\"H4: Atypical Resolution-Linked Pattern of SPM Receptor Desensitization\",\"description\":\"ALX/FPR2 and GPR32 evolved specialized desensitization mechanisms coupling receptor activation to pro-resolving effects without classical internalization. SPM engagement induces PDZ scaffold protein recruitment sustaining signaling through compartmentalization. LOW PRIORITY: Most speculative hypothesis with circular reasoning, no proposed testable molecular mechanism, and contradicts well-established GPCR biology. Extraordinary evidence required given evolutionary conservation of desensitization mechanisms.\",\"target_gene\":\"ALX/FPR2, GPR32, PDZ scaffold proteins\",\"composite_score\":0.44,\"evidence_for\":[{\"claim\":\"Emerging evidence suggests SPM receptors signal within specialized resolution domains\",\"pmid\":\"26602809\"},{\"claim\":\"Physiological requirement for sustained resolution signaling over hours to days\",\"pmid\":\"NA\"}],\"evidence_against\":[{\"claim\":\"Circular reasoning: assumes sustained signaling is required and that evolution adapted receptors for this purpose\",\"pmid\":\"NA\"},{\"claim\":\"No specific PDZ protein identified; PDZ domain proteins include hundreds of family members\",\"pmid\":\"NA\"},{\"claim\":\"Contrasts with well-established GPCR biology: virtually all characterized GPCRs undergo regulatory feedback\",\"pmid\":\"NA\"},{\"claim\":\"Resolution of inflammation is self-limited process characterized by shutdown of signals, not continuous signaling\",\"pmid\":\"NA\"}]}],\"synthesis_summary\":\"The integration of theoretical, critical, and feasibility perspectives reveals that H1 (ALX/FPR2 ligand-dependent β-arrestin bias) and H5 (differential SPM desensitization susceptibility) represent the most viable avenues for SPM receptor drug development, with composite scores of 0.72 and 0.65 respectively. Both hypotheses share mechanistic support from biased agonism studies but diverge on therapeutic strategy: H1 suggests avoiding desensitization through biased agonists while H5 suggests selecting SPMs with favorable desensitization profiles. H6 presents a potentially complementary mechanism where β-arrestin recruitment paradoxically generates protective feedback, though it conflicts with H1's strategy and requires careful context evaluation. H3 and H7 offer important clinical insights (patient stratification, heterodimer effects) but face significant druggability barriers. H2 and H4 should be deprioritized due to speculative mechanisms lacking direct experimental evidence, though H2 may warrant targeted basic research to establish fundamental GPR32 biology.\",\"knowledge_edges\":[{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"ALX/FPR2\",\"target_type\":\"receptor\",\"relation\":\"mechanistic_basis\"},{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"H5\",\"target_type\":\"hypothesis\",\"relation\":\"shares_mechanistic_framework\"},{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"H6\",\"target_type\":\"hypothesis\",\"relation\":\"conflicting_strategy\"},{\"source_id\":\"H5\",\"source_type\":\"hypothesis\",\"target_id\":\"RvD1\",\"target_type\":\"ligand\",\"relation\":\"prioritization_criterion\"},{\"source_id\":\"H5\",\"source_type\":\"hypothesis\",\"target_id\":\"LXA4\",\"target_type\":\"ligand\",\"relation\":\"prioritization_criterion\"},{\"source_id\":\"H6\",\"source_type\":\"hypothesis\",\"target_id\":\"β-arrestin1/2\",\"target_type\":\"protein\",\"relation\":\"downstream_effector\"},{\"source_id\":\"H6\",\"source_type\":\"hypothesis\",\"target_id\":\"p38 MAPK\",\"target_type\":\"protein\",\"relation\":\"signaling_pathway\"},{\"source_id\":\"H3\",\"source_type\":\"hypothesis\",\"target_id\":\"PKC isoforms\",\"target_type\":\"protein\",\"relation\":\"mediator\"},{\"source_id\":\"H3\",\"source_type\":\"hypothesis\",\"target_id\":\"TNF-α\",\"target_type\":\"cytokine\",\"relation\":\"desensitizing_agent\"},{\"source_id\":\"H7\",\"source_type\":\"hypothesis\",\"target_id\":\"FPR2/FPR1 heterodimer\",\"target_type\":\"receptor_complex\",\"relation\":\"modifies_desensitization\"},{\"source_id\":\"H2\",\"source_type\":\"hypothesis\",\"target_id\":\"GPR32\",\"target_type\":\"receptor\",\"relation\":\"target\"},{\"source_id\":\"H2\",\"source_type\":\"hypothesis\",\"target_id\":\"GRK6\",\"target_type\":\"kinase\",\"relation\":\"mediator\"},{\"source_id\":\"H4\",\"source_type\":\"hypothesis\",\"target_id\":\"PDZ scaffold proteins\",\"target_type\":\"protein\",\"relation\":\"scaffold_complex\"}]}",
  "tokens_used": "3021"
}